IL129344A0 - Novel integrin receptor antagonists - Google Patents

Novel integrin receptor antagonists

Info

Publication number
IL129344A0
IL129344A0 IL12934497A IL12934497A IL129344A0 IL 129344 A0 IL129344 A0 IL 129344A0 IL 12934497 A IL12934497 A IL 12934497A IL 12934497 A IL12934497 A IL 12934497A IL 129344 A0 IL129344 A0 IL 129344A0
Authority
IL
Israel
Prior art keywords
compounds
receptor antagonists
integrin receptor
cell adhesion
novel integrin
Prior art date
Application number
IL12934497A
Other languages
English (en)
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of IL129344A0 publication Critical patent/IL129344A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL12934497A 1996-11-27 1997-11-26 Novel integrin receptor antagonists IL129344A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3320896P 1996-11-27 1996-11-27
PCT/US1997/021596 WO1998023608A1 (en) 1996-11-27 1997-11-26 Novel integrin receptor antagonists

Publications (1)

Publication Number Publication Date
IL129344A0 true IL129344A0 (en) 2000-02-17

Family

ID=21869102

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12934497A IL129344A0 (en) 1996-11-27 1997-11-26 Novel integrin receptor antagonists

Country Status (12)

Country Link
US (2) US6130231A (de)
EP (1) EP0944619B1 (de)
JP (1) JP2001527527A (de)
AT (1) ATE342262T1 (de)
AU (1) AU5362998A (de)
CA (1) CA2272565A1 (de)
DE (1) DE69736812T2 (de)
DK (1) DK0944619T3 (de)
ES (1) ES2270475T3 (de)
IL (1) IL129344A0 (de)
PT (1) PT944619E (de)
WO (1) WO1998023608A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
EP1131306A2 (de) 1998-11-18 2001-09-12 Du Pont Pharmaceuticals Company Isoxazolin fibrinogen-rezeptor-antagonisten
US6319937B1 (en) 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
NZ511677A (en) 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2003505416A (ja) 1999-07-21 2003-02-12 ワイス αｖβ３インテグリンに対して選択的な二環式拮抗薬
WO2001024828A2 (en) * 1999-10-06 2001-04-12 Basf Aktiengesellschaft MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
WO2001097848A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1372720A4 (de) * 2001-03-02 2006-07-26 Medimmune Inc Verfahren zur prävention oder behandlung von entzündlichen erkrankungen oder autoimmunkrankheiten durch verabreichung von integrin-alphav-beta3-antagonisten
WO2003013346A2 (en) 2001-08-08 2003-02-20 Bristol-Myers Squibb Pharma Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
KR100978126B1 (ko) 2002-01-24 2010-08-26 반즈 쥬이쉬 하스피털 인테그린 표적화 조영제
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
EP1487492A4 (de) * 2002-03-04 2008-10-01 Medimmune Inc Prävention oder behandlung von krebs mit integrin alphavbeta3 antagonisten in kombination mit anderen mitteln
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
CA2481747A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
WO2004026252A2 (en) * 2002-09-23 2004-04-01 The Regents Of The University Of Michigan Glioma treatments
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP1613273B1 (de) * 2003-04-11 2012-06-13 MedImmune, LLC Rekombinante il-9-antikörper und ihre verwendung
CN102977015B (zh) 2003-06-06 2015-05-06 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
MXPA06000675A (es) * 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
PL1682537T3 (pl) 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
US7371381B2 (en) * 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
CA2559889A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1809326A4 (de) 2004-10-27 2009-11-04 Medimmune Inc Modulation von antikörperspezifität mittels anpassung der affinität zu verwandten antigenen
LT2444079T (lt) 2005-05-17 2017-03-27 Sarcode Bioscience Inc. Kompozicijos ir būdai, skirti akių sutrikimų gydymui
US7928120B2 (en) 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
CN101460497A (zh) * 2006-04-04 2009-06-17 菲布罗根有限公司 作为hif调节剂的吡咯并吡啶和噻唑并吡啶化合物
JP2009535126A (ja) * 2006-04-27 2009-10-01 バーンズ−ジューイッシュ ホスピタル 標的組織の検出とイメージング
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA3177366A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
AU2007303465A1 (en) * 2006-09-29 2008-04-10 Washington University Combinations for treatment of neovasculature
MX367292B (es) 2006-12-26 2019-08-13 Lantheus Medical Imaging Inc Ligandos para formacion de imagen de inervacion cardiaca.
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
US20090155176A1 (en) * 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
EP2265125B1 (de) * 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topische lfa-1-antagonisten zur verwendung bei der lokalen behandlung von immunerkrankungen
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
EP2276508A4 (de) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Freisetzung von lfa-1-antagonisten gegen das magen-darm-system
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104470899B (zh) 2012-03-09 2017-12-26 菲布罗根有限公司 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
MY171483A (en) 2012-07-16 2019-10-15 Fibrogen Inc Process for making isoquinoline compounds
RS57795B1 (sr) 2012-07-16 2018-12-31 Fibrogen Inc Kristalni oblici inhibitora prolil hidroksilaze
EP3715345B8 (de) 2012-07-25 2024-05-29 Bausch + Lomb Ireland Limited Herstellung eines lfa-1-hemmers
WO2014116849A1 (en) 2013-01-24 2014-07-31 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
CA2961935C (en) 2013-09-24 2020-09-08 Hirofumi Fukunaga Nitrogen-containing compound or salt thereof, or metal complex thereof
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
DK3275883T3 (da) 2015-03-25 2021-06-28 Fujifilm Corp Fremgangsmåde til produktion af ny nitrogenholdig forbindelse eller salt deraf, og mellemprodukt deraf
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW301607B (de) * 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
JP3088016B2 (ja) * 1993-03-29 2000-09-18 ゼネカ・リミテッド 血小板凝集抑制剤としての複素環式化合物
US5622967A (en) * 1993-04-26 1997-04-22 Sterling Winthrop, Inc. Quinolone carboxamide Calpain inhibitors
EP0702671A4 (de) * 1993-06-09 1996-06-19 Smithkline Beecham Corp Bicyclische fibrinogen-antagonisten
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6117910A (en) * 1994-12-13 2000-09-12 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists

Also Published As

Publication number Publication date
EP0944619A1 (de) 1999-09-29
DE69736812D1 (de) 2006-11-23
DE69736812T2 (de) 2007-08-09
CA2272565A1 (en) 1998-06-04
ATE342262T1 (de) 2006-11-15
DK0944619T3 (da) 2007-02-05
US6130231A (en) 2000-10-10
AU5362998A (en) 1998-06-22
ES2270475T3 (es) 2007-04-01
US6358976B1 (en) 2002-03-19
PT944619E (pt) 2007-01-31
WO1998023608A1 (en) 1998-06-04
EP0944619B1 (de) 2006-10-11
JP2001527527A (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
IL129344A0 (en) Novel integrin receptor antagonists
WO1999050249A3 (en) Pyrimidines and triazines as integrin antagonists
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
DK1196397T3 (da) Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
FR2712812B1 (fr) Composition pour la production de produits thérapeutiques in vivo.
AU2450197A (en) Alphavbeta3 antagonists
UA74419C2 (uk) Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69720771D1 (en) Integrin antagonist
PL341095A1 (en) Compounds acting as antagonists of integrin receptor
DE69829996D1 (de) Integrin-rezeptor-antagonisten
DE69821132T2 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DE60038686D1 (de) Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten
GB9923078D0 (en) Sapogenin derivatives and their use
EP1246619A4 (de) Urotensin-ii rezeptorantagonisten
YU38200A (sh) Antagonisti integrinskog receptora